Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India mulls legal action against US think tank's 'smear' campaign

This article was originally published in Scrip

Executive Summary

Even as India's Prime Minister Narendra Modi is set to begin his high profile five-day visit to the US showcasing the country's best side to top global investors, senior government officials were engaged in a major fire-fighting exercise over allegations against the quality of medicines from India.

You may also be interested in...



Obituary: Indian Generics Industry Torchbearer Dilip Shah

Indian industry veteran and secretary general of the Indian Pharmaceutical Alliance, Dilip Shah, has died aged 77. Shah, a former commercial director of Pfizer in India, played a pivotal role in ensuring that the Indian generic industry's voice was heard.

WTO Chief: Pharma Needs To 'Lift The Veil Of Opaqueness' In COVID-19 Vaccine Contracts

WTO director general says pharma could have done more on voluntary licensing for COVID-19 vaccines and also calls for better transparency of pricing and contracts to ensure “a level playing field” when it comes to saving lives.

Cipla CEO On Lung Leadership Beyond Asthma, AMR Plans

CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.

Topics

Related Companies

UsernamePublicRestriction

Register

SC026471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel